pixantrone has been researched along with mitoxantrone in 12 studies
| Studies (pixantrone) | Trials (pixantrone) | Recent Studies (post-2010) (pixantrone) | Studies (mitoxantrone) | Trials (mitoxantrone) | Recent Studies (post-2010) (mitoxantrone) |
|---|---|---|---|---|---|
| 92 | 16 | 59 | 4,555 | 1,042 | 1,004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gallagher, CE; Getahun, Z; Giuliani, FC; Hacker, MP; Krapcho, AP; Landi, JJ; Maresch, MJ; Petry, ME; Polsenberg, JF; Stallman, J | 1 |
| Hacker, MP; Hazlehurst, LA; Krapcho, AP | 1 |
| Gonsette, RE | 1 |
| Biagioli, T; Cavaletti, G; Cavalletti, E; Crippa, L; Dassi, M; Di Luccio, E; Frigo, M; Galbiati, S; Lolli, F; Mazzanti, B; Oggioni, N; Perseghin, P; Riccio, P; Rigolio, R; Rota, S; Sala, F; Sala, V; Stanzani, L; Tagliabue, E; Tredici, G; Zoia, C | 1 |
| Dubois, B; Gonsette, RE | 1 |
| Bellini, O; Cavagnoli, R; Cavalletti, E; Crippa, L; Mainardi, P; Oggioni, N; Sala, F | 1 |
| Caccialanza, G; Carotti, A; Catto, M; Colombo, R; De Lorenzi, E; Lanni, C; Racchi, M; Verga, L | 1 |
| Bilardi, RA; Buck, DP; Collins, JG; Cutts, SM; Evison, BJ; Mansour, OC; Nudelman, A; Phillips, DR; Rephaeli, A; Sleebs, BE; Watson, KG | 1 |
| Chello, M; Covino, E; Menna, P; Minotti, G; Paz, OG; Salvatorelli, E; Singer, JW | 1 |
| Bertoni, F; Cattan, V; Egorov, A; Han, H; Minotti, G | 1 |
| Alonso Caballero, C; Barrenetxea Lekue, C; D'Amore, F; Grasso Cicala, S; Herráez Rodríguez, S; Jørgensen, JM; Leal Martínez, I; Leppä, S; Stauffer Larsen, T; Toldbod, H | 1 |
| Ahonen, T; Airavaara, M; Kalso, E; Leino, S; Mätlik, K; Moreira, VM; Rinne, M; Salminen, O; Vedovi, F; Xhaard, H; Yli-Kauhaluoma, J; Zappia, G | 1 |
4 review(s) available for pixantrone and mitoxantrone
| Article | Year |
|---|---|
A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Topics: Adjuvants, Immunologic; Antioxidants; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Administration Schedule; Humans; Immunosuppressive Agents; Isoquinolines; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents | 2004 |
Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Heart; Humans; Immunosuppressive Agents; Immunotherapy; Isoquinolines; Mitoxantrone; Multiple Sclerosis | 2004 |
Pixantrone: novel mode of action and clinical readouts.
Topics: Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Mitoxantrone; Survival Rate | 2018 |
Pixantrone beyond monotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, B-Cell; Mitoxantrone; Prednisone; Rituximab; Salvage Therapy; Vidarabine; Vincristine | 2019 |
8 other study(ies) available for pixantrone and mitoxantrone
| Article | Year |
|---|---|
6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
Topics: Adenocarcinoma; Animals; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Humans; Isoquinolines; Leukemia L1210; Leukemia P388; Male; Mice; Mice, Inbred DBA; Mitoxantrone; Structure-Activity Relationship; Tumor Cells, Cultured | 1994 |
Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Division; DNA Damage; DNA, Single-Stranded; Drug Resistance; Drug Screening Assays, Antitumor; Isoquinolines; Leukemia L1210; Mitoxantrone; Proteins; Tumor Cells, Cultured | 1995 |
Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.
Topics: Acute Disease; Animals; Cell Division; Cells, Cultured; Chronic Disease; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Immunosuppressive Agents; Isoquinolines; Lymphocyte Count; Mitoxantrone; Rats; T-Lymphocytes | 2004 |
Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.
Topics: Animals; Antineoplastic Agents; Cardiomyopathies; Doxorubicin; Drug Interactions; Female; Heart; Isoquinolines; Mice; Mitoxantrone; Myocardium; Time Factors | 2007 |
CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Cell Line, Tumor; Cell Survival; Electrophoresis, Capillary; Humans; Isoquinolines; Microscopy, Electron, Transmission; Mitoxantrone; Neuroprotective Agents; Particle Size; Peptide Fragments; Plaque, Amyloid; Protein Multimerization; Spectrometry, Fluorescence; Suramin; Thiazoles | 2009 |
New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; DNA Adducts; DNA-Directed RNA Polymerases; Drug Screening Assays, Antitumor; Escherichia coli Proteins; Formaldehyde; Humans; Hydrogen-Ion Concentration; Isoquinolines; Mitoxantrone; Models, Molecular; Prodrugs; Structure-Activity Relationship; Transcription, Genetic | 2010 |
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Topics: Aged; Antibiotics, Antineoplastic; Biotransformation; Chromatography, High Pressure Liquid; Doxorubicin; Drug Synergism; Female; Heart; Humans; Hydrogen Peroxide; In Vitro Techniques; Isoquinolines; Male; Mitoxantrone; Molecular Structure; Myocardium; Oxidation-Reduction; Superoxides | 2013 |
Mitoxantrone, pixantrone and mitoxantrone (2-hydroxyethyl)piperazine are toll-like receptor 4 antagonists, inhibit NF-κB activation, and decrease TNF-alpha secretion in primary microglia.
Topics: Isoquinolines; Microglia; Mitoxantrone; NF-kappa B; Piperazine; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2020 |